Technology · 14/10/2026
EMA Approves Paediatric Investigation Plan for Opdualag and Two Other Cancer Treatments
The European Medicines Agency (EMA) has agreed to investigate Opdualag, nivolumab, and relatlimab for use in children with certain types of cancer, including benign, malignant, and unspecified neoplasms.